NCT04202354View on ClinicalTrials.gov

Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 3, 2020

Primary Completion Date

September 3, 2021

Study Completion Date

September 3, 2021

Conditions
Non-alcoholic Steatohepatitis
Interventions
DRUG

ARO-HSD Injection

single or multiple doses of ARO-HSD by subcutaneous (sc) injections

DRUG

sterile normal saline (0.9% NaCl)

calculated volume to match active treatment, by sc injection

Trial Locations (1)

1010

Auckland Clinical Studies, Grafton

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY